NK510

Phase 1Small molecule

BBase Therapeutics (Shanghai) Co., Ltd.

NK510 is one of 133 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 1.

Indications

Total Trials

Active Trials

132

Competitors

Pipeline

Status by Indication[3][1]

Indication

Systemic Lupus ErythematosusActive, not recruiting

Colorectal CancerActive, not recruiting

Gastric CancerActive, not recruiting

Soft Tissue SarcomaActive, not recruiting

Systemic Lupus ErythematosusPreclinical

Active, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

Gastric CancerPhase 1

Active, not recruiting

Soft Tissue SarcomaPhase 1

Active, not recruiting

Competition

Competitive Landscape

949 competitors in Colorectal Cancer

#DrugCompanyPhaseTrials

Eylea

Regeneron

Preclinical

5 2

PORTRAZZA

Emend IV

Versed

CConrado Roberto Hoffmann Filho

Preclinical

1 5

Ketalar

AAultman Health Foundation

Preclinical

1 6

Ultiva

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Preclinical

1 7

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 8

Bridion

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 9

Andriol

AAuxilium

Preclinical

1 10

Feraheme

AAzurity Pharmaceuticals

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

N/ANot yet recruiting

Systemic Lupus Erythematosus

NCT07083349

Q4 2027

Phase 1Not yet recruiting

Colorectal Cancer

NCT07166263

Q1 2031

Phase 1/2Not yet recruiting

Rare Tumor

NCT07307053

Clinical

Trials by Indication[1]

Safety and Efficacy1 trial

Safety and Efficacy of NK510 to Treat NSCLC

Recruiting·BBase Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT06097962·12 enrolled

Soft Tissue Sarcoma1 trial

Safety and Efficacy of NK510 to Treat Osteosarcoma and Soft Tissue Sarcoma

Unknown status·BBase Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT06117878·12 enrolled

Systemic Lupus Erythematosus1 trial

NK510 Cell Therapy for Refractory Systemic Lupus Erythematosus

Not yet recruiting·BBase Therapeutics (Shanghai) Co., Ltd.·N/A·NCT07083349·9 enrolled

Colorectal Cancer1 trial

Safety and Efficacy of NK510 to Treat Gastric Cancer and Colorectal Cancer

Not yet recruiting·BBase Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT07166263·15 enrolled

Gastric Cancer1 trial

Safety and Efficacy of NK510 to Treat Gastric Cancer

Unknown status·BBase Therapeutics (Shanghai) Co., Ltd.·Phase 1·NCT06098898·9 enrolled

1 more indication

Rare Tumor1 trial

Rare Tumor Focused Platform Study of Innovative Therapies and Technologies (PLATFORM2)

Not yet recruiting·—·Phase 1/2·NCT07307053·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for NK510. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — NK510 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for NK510. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Base Therapeutics (Shanghai) Co., Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: BBase Therapeutics (Shanghai) Co., Ltd.

NK510

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q4 2027

Q1 2031

Trials by Indication[1]

Safety and Efficacy1 trial

Soft Tissue Sarcoma1 trial

Systemic Lupus Erythematosus1 trial

Colorectal Cancer1 trial

Gastric Cancer1 trial

Rare Tumor1 trial

References

Drug Info

Quick Facts

Related News